Qualigen Therapeutics ( (QLGN) ) has issued an update.
Qualigen Therapeutics is executing a 1-for-50 reverse stock split to boost its stock price and meet Nasdaq’s listing requirements, effective November 5, 2024. This move will consolidate every 50 shares into one, reducing outstanding shares from 36.7 million to around 737,000, while maintaining the number of authorized shares. Investors holding fractional shares will receive cash compensation.
Find detailed analytics on QLGN stock on TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
